Summit Therapeutics slides after mixed data for lung cancer drug

Summit Therapeutics

08/09/2025 12:21

** Summit Therapeutics SMMT.O falls 21.56% to $20.38 premarket

** Co and partner Akeso 9926.HK said on Sunday its lung cancer drug showed "improving, favorable trend" in overall survival during a late-stage trial

** However, some analysts raised questions on the data for the drug, ivonescimab, seen in patients in China and Western countries

** The details on the Asian vs. non-Asian subgroups were worse than we expected, brokerage Piper Sandler says

** Up to last close, stock up ~46% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))